2025-06-13-Jefferies-清晰医疗（CU6）_澳大利亚医疗保健_CU6_AU_-前列腺癌和神经内分泌肿瘤的二期试验积极结果_7页_97kb

报告摘要

Clarity Pharmaceuticals (CU6 AU) Equity Research Summary

Date: June 12, 2025
Jefferies Equity Research maintains a "Buy" recommendation for Clarity Pharmaceuticals Ltd (CU6 AU) with a price target of A$4.70. Positive Phase 2 trial results for diagnostic agents targeting prostate cancer (PCa) and neuroendocrine tumors (NETs) align with the research firm's timelines, highlighting progress in key therapeutic areas.

Phase 2 Trial Overviews

SABRE Trial (Prostate Cancer Imaging)

Key Outcomes: Topline data from the diagnostic Phase 2 SABRE trial demonstrated that 64Cu-SAR-Bombesin is safe, well-tolerated, and effective for detecting prostate cancer in patients with biochemical recurrence, particularly in cases negative on standard-of-care PSMA PET scans. This includes potential utility in PSMA-negative PCa due to its targeting of GRPR receptors.

DISCO Trial (Neuroendocrine Tumors Imaging)

Key Outcomes: DISCO trial results confirm that 64Cu-SARTATE is safe and effective compared to standard-of-care imaging for NET lesions. At both 4 and 20 hours post-administration, it detected more lesions (393-488 vs. 186-265) in study participants. Clarity is proceeding to a registrational Phase 3 study in NETs.

JEF Views

Both trials align with the firm's expected timeline, and successful outcomes support a positive re-rating of CU6's share price. Initial discussion for next steps includes advancing the SABRE program.

Valuation and Pipeline Highlights

Clarity has three major commercial opportunities: PSMA-positive/prostate cancer imaging/treatment, NET imaging, and PSMA-negative PCa imaging. The valuation incorporates risk-weighted pipeline assessments to set the A$4.70 price target.
Upside risks include success in ongoing clinical trials, which could drive re-rating. Downside risks involve uncertainties in late-stage trials and regulatory approvals, despite positive preclinical and early clinical data.

Analyst Credentials

Authors: David Stanton, MD and Vanessa Thomson, MD, both employed by Jefferies (Australia) Pty Ltd and certified that their compensation is not tied to recommendations. No FINRA registration in the US due to non-affiliation.

Disclaimer

This report is for Jefferies clients only and contains extensive risk disclosures, including conflicts of interest. Prior performance does not guarantee future results, and investment decisions should consider individual circumstances. Specific disclosures vary by jurisdiction (e.g., Australia, Canada, Singapore).

展开完整摘要